These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37815914)

  • 1. MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer.
    Crowell PD; Giafaglione JM; Jones AE; Nunley NM; Hashimoto T; Delcourt AML; Petcherski A; Agrawal R; Bernard MJ; Diaz JA; Heering KY; Huang RR; Low JY; Matulionis N; Navone NM; Ye H; Zoubeidi A; Christofk HR; Rettig MB; Reiter RE; Haffner MC; Boutros PC; Shirihai OS; Divakaruni AS; Goldstein AS
    Cell Rep; 2023 Oct; 42(10):113221. PubMed ID: 37815914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
    Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
    Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen-induced expression of DRP1 regulates mitochondrial metabolic reprogramming in prostate cancer.
    Lee YG; Nam Y; Shin KJ; Yoon S; Park WS; Joung JY; Seo JK; Jang J; Lee S; Nam D; Caino MC; Suh PG; Chan Chae Y
    Cancer Lett; 2020 Feb; 471():72-87. PubMed ID: 31838085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation.
    Gao L; Schwartzman J; Gibbs A; Lisac R; Kleinschmidt R; Wilmot B; Bottomly D; Coleman I; Nelson P; McWeeney S; Alumkal J
    PLoS One; 2013; 8(5):e63563. PubMed ID: 23704919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion of androgen receptor signaling from a growth suppressor in normal prostate epithelial cells to an oncogene in prostate cancer cells involves a gain of function in c-Myc regulation.
    Vander Griend DJ; Litvinov IV; Isaacs JT
    Int J Biol Sci; 2014; 10(6):627-42. PubMed ID: 24948876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex.
    Nyquist MD; Coleman IM; Lucas JM; Li D; Hanratty B; Meade H; Mostaghel EA; Plymate SR; Corey E; Haffner MC; Nelson PS
    Cancer Res; 2023 Sep; 83(17):2938-2951. PubMed ID: 37352376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer.
    Mao F; Li J; Luo Q; Wang R; Kong Y; Carlock C; Liu Z; Elzey BD; Liu X
    Mol Cancer Ther; 2018 Jul; 17(7):1554-1565. PubMed ID: 29716963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased Akt signaling resulting from the loss of androgen responsiveness in prostate cancer.
    Dulinska-Litewka J; McCubrey JA; Laidler P
    Curr Med Chem; 2013; 20(1):144-57. PubMed ID: 23033951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the KDM4B-AR-c-Myc axis promotes sensitivity to androgen receptor-targeted therapy in advanced prostate cancer.
    Tang DE; Dai Y; He JX; Lin LW; Leng QX; Geng XY; Fu DX; Jiang HW; Xu SH
    J Pathol; 2020 Oct; 252(2):101-113. PubMed ID: 32617978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells.
    Nadiminty N; Tummala R; Lou W; Zhu Y; Zhang J; Chen X; eVere White RW; Kung HJ; Evans CP; Gao AC
    J Biol Chem; 2012 Jan; 287(2):1527-37. PubMed ID: 22128178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SREBF1 Activity Is Regulated by an AR/mTOR Nuclear Axis in Prostate Cancer.
    Audet-Walsh É; Vernier M; Yee T; Laflamme C; Li S; Chen Y; Giguère V
    Mol Cancer Res; 2018 Sep; 16(9):1396-1405. PubMed ID: 29784665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer.
    Nadiminty N; Tummala R; Liu C; Lou W; Evans CP; Gao AC
    Mol Cancer Ther; 2015 Aug; 14(8):1884-95. PubMed ID: 26056150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual targeting of androgen receptor and mTORC1 by salinomycin in prostate cancer.
    Mirkheshti N; Park S; Jiang S; Cropper J; Werner SL; Song CS; Chatterjee B
    Oncotarget; 2016 Sep; 7(38):62240-62254. PubMed ID: 27557496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting KDM4B that coactivates c-Myc-regulated metabolism to suppress tumor growth in castration-resistant prostate cancer.
    Wu MJ; Chen CJ; Lin TY; Liu YY; Tseng LL; Cheng ML; Chuu CP; Tsai HK; Kuo WL; Kung HJ; Wang WC
    Theranostics; 2021; 11(16):7779-7796. PubMed ID: 34335964
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer.
    Labrecque MP; Brown LG; Coleman IM; Nguyen HM; Dalrymple S; Brennen WN; Isaacs JT; Li D; Lakely B; DeLucia DC; Lee JK; Schweizer MT; Lin DW; Corey E; Nelson PS; Morrissey C
    Prostate; 2024 Jan; 84(1):100-110. PubMed ID: 37796107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer.
    Coleman DJ; Gao L; Schwartzman J; Korkola JE; Sampson D; Derrick DS; Urrutia J; Balter A; Burchard J; King CJ; Chiotti KE; Heiser LM; Alumkal JJ
    Sci Rep; 2019 Mar; 9(1):3823. PubMed ID: 30846826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A long noncoding RNA connects c-Myc to tumor metabolism.
    Hung CL; Wang LY; Yu YL; Chen HW; Srivastava S; Petrovics G; Kung HJ
    Proc Natl Acad Sci U S A; 2014 Dec; 111(52):18697-702. PubMed ID: 25512540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc.
    Chuu CP; Kokontis JM; Hiipakka RA; Fukuchi J; Lin HP; Lin CY; Huo C; Su LC; Liao S
    Cancer Sci; 2011 Nov; 102(11):2022-8. PubMed ID: 21781227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cells.
    Safi R; Wardell SE; Watkinson P; Qin X; Lee M; Park S; Krebs T; Dolan EL; Blattler A; Tsuji T; Nayak S; Khater M; Fontanillo C; Newlin MA; Kirkland ML; Xie Y; Long H; Fink EC; Fanning SW; Runyon S; Brown M; Xu S; Owzar K; Norris JD; McDonnell DP
    Nat Commun; 2024 Sep; 15(1):7675. PubMed ID: 39227594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.